Please assess the completion status of the following clinical trial:

Trial Title: Effect of Anti-IgE in Chronic Urticaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant, non-breastfeeding females~* Chronic urticaria defined as symptoms \>50% of the days or 3 days per week for more than 12 weeks~* History of angioedema~* Chronic daily therapy with anti-histamines and stable doses of antihistamines for at least 4 weeks.~* High baseline score for pruritis (at least 2 on a 3 point scale)~* No other etiology identified for chronic urticaria such as drug-related or physical urticaria as determined by history, physical examination and laboratory studies~Exclusion Criteria:~* Concomitant use of systemic corticosteroids for 1 month prior to enrollment. Topical steroid use will not be permitted, but inhaled topical steroids are allowed.~* Current use of immunosuppressive medication (cyclosporine, IVIg, methotrexate, cyclophosphamide). Any such medication will be discontinued for at least 6 weeks before screening.~* Treatment with any investigational agent within 30 days of screening~* Previous treatment with omalizumab~* Recent history of drug or alcohol abuse (within 3 years prior to study)~* Active atopic dermatitis requiring the use of topical steroid agents~* Clinically relevant cardiovascular, hepatic, neurologic, psychiatric, endocrine, or other major systemic disease making the protocol or interpretation of the study results difficult.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).